Jaap Oostendorp - Concepedia

Concepedia

Author

Jaap Oostendorp

Leiden University Medical Center

Also Known As

J G Oostendorp, J. G. Oostendorp, J. Oostendorp, J.G. Oostendorp, Jaap Oostendorp

65

Publications

4.1K

Citations

23

H-Index

79

Concepts

All Affiliations

Leiden University Medical Center ISA Pharmaceuticals (Netherlands)University of Groningen University Medical Center Groningen Institute of Haematology and Blood Transfusion

JO

About

Jaap Oostendorp is an author at Leiden University Medical Center specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	739
2	Allergy	3	3	65
3	Engineering	2	2	133
4	Health Sciences	1	1	17
5	Public Health	1	1	68

Jaap Oostendorp

×

33

Publications

4.1K

Citations

23

H-Index

	Year	Citations
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia Gemma G. Kenter, Marij J.P. Welters, A. Rob P.M. Valentijn, New England Journal of Medicine	2009	1.1K
Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine Marij J.P. Welters, Gemma G. Kenter, Sytse J. Piersma, Clinical Cancer Research	2008	365
Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity Gemma G. Kenter, Marij J.P. Welters, A. Rob P.M. Valentijn, Clinical Cancer Research	2008	308
CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses Rodney Alexander Rosalia, Luis J. Cruz, Suzanne van Duikeren, Biomaterials VaccinationNanomedicineCross-protectionTumor ImmunologyImmunology	2014	265
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses Marij J.P. Welters, Gemma G. Kenter, Peggy J. de Vos van Steenwijk, Proceedings of the National Academy of Sciences	2010	236
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T‐cell activation Rodney Alexander Rosalia, Esther D. Quakkelaar, Anke Redeker, European Journal of Immunology	2013	204
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial Mariëtte I.E. van Poelgeest, Marij J.P. Welters, Edith M.G. van Esch, Journal of Translational Medicine	2013	186
Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer Frank M. Speetjens, Peter J.K. Kuppen, Marij J.P. Welters, Clinical Cancer Research	2009	177
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response Mariëtte I.E. van Poelgeest, Marij J.P. Welters, Renee Vermeij, Clinical Cancer Research	2016	163
Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial Ninke Leffers, Annechien J.A. Lambeck, Marloes J.M. Gooden, International Journal of Cancer	2009	140

Page 1